Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Condylomata Acuminata 2Anus Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1Persistent Infection 1Papillomavirus Infections 1Glioblastoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Cisplatin 2entinostat 1bintrafusp alfa protein, human 1Vaccines 1Surveys and Questionnaires 1Specimen Handling 1Papillomavirus Vaccines 1Observation 1Nivolumab 1Ipilimumab 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1CTLA-4 Antigen 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Vulvar Neoplasms × Vaccines × Clear all
NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Beijing Health Guard Biotechnology, Inc

Phase 3 Active not recruiting
2,750 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡